Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

Josep Garcia; Herbert I. Hurwitz; Alan B. Sandler; David Miles; Robert L. Coleman; Regula Deurloo; Olivier Chinot

doi:10.1016/j.ctrv.2020.102017

Keywords

BevacizumabMedicineCancerOncologyLung cancerTargeted therapyClinical trialCombination therapyMetastatic breast cancerColorectal cancerInternal medicineOvarian cancerBreast cancerChemotherapy

Affiliated Institutions

Related Publications

Comprehensive review of targeted therapy for colorectal cancer

Yuanhong Xie , Yingxuan Chen , Jing‐Yuan Fang

Abstract Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery a...

2020 Signal Transduction and Targeted Therapy 1552 citations

VEGF as a Therapeutic Target in Cancer

Napoleone Ferrara

Tumors require nutrients and oxygen in order to grow, and new blood vessels, formed by the process of angiogenesis, provide these substrates. The key mediator of angiogenesis is...

2005 Oncology 568 citations

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

Mario Roselli , Vittore Cereda , Maria Giovanna di Bari +8 more

Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, "standard-of-care" anticancer therapies, includi...

2013 OncoImmunology 184 citations

Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

Abby B. Siegel , E. Cohen , Allyson J. Ocean +13 more

Purpose To determine the clinical and biologic effects of bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carc...

2008 Journal of Clinical Oncology 505 citations

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

David S. Ettinger , Douglas E. Wood , Dara L. Aisner +39 more

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosi...

2022 Journal of the National Comprehensive... 1326 citations

Publication Info

Year: 2020
Type: review
Volume: 86
Pages: 102017-102017
Citations: 1040
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1040

OpenAlex

Cite This

APA Style

                            
                                    Josep Garcia, 
                                
                                    Herbert I. Hurwitz, 
                                
                                    Alan B. Sandler
                                
                                et al.
                            
                            (2020). 
                            Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. 
                            Cancer Treatment Reviews
                            , 86
                            
                            , 102017-102017.
                            https://doi.org/10.1016/j.ctrv.2020.102017

Identifiers

DOI: 10.1016/j.ctrv.2020.102017